MARKET

BIVI

BIVI

Biovie Inc
NASDAQ
2.910
-1.000
-25.58%
Pre Market: 1.750 -1.16 -39.86% 07:00 08/08 EDT
OPEN
3.980
PREV CLOSE
3.910
HIGH
3.980
LOW
2.860
VOLUME
57.01K
TURNOVER
0
52 WEEK HIGH
75.00
52 WEEK LOW
2.860
MARKET CAP
5.40M
P/E (TTM)
-0.1377
1D
5D
1M
3M
1Y
5Y
1D
Reported Earlier, BioVie Prices $12M Public Offering Of 6M Units Consisting Of Common Stock And Warrants At $2.00 Per Unit
Benzinga · 3h ago
BioVie stock dips on pricing $12M securities offering
Seeking Alpha · 4h ago
*BioVie: Each Warrant Immediately Exercisable, Entitle Holder to Purchase One Share at $2.50 Per Shar >BIVI
Dow Jones · 9h ago
*BioVie: Proceeds for Working Capital, General Corporate Purposes. >BIVI
Dow Jones · 9h ago
*BioVie Prices Underwritten Public Offering of 6,000,000 Units at $2.00 Per Unit >BIVI
Dow Jones · 9h ago
*BioVie: Gross Proceeds From Offering Expected to Be Approximately $12M>BIVI
Dow Jones · 9h ago
*BioVie: Each Unit Consisting of One Share of Common Stock and One Warrant >BIVI
Dow Jones · 9h ago
*BioVie: Warrabts Will Expire Five Years From Date of Issuance >BIVI
Dow Jones · 9h ago
More
About BIVI
BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Webull offers BioVie Inc stock information, including NASDAQ: BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.